USFDA inspection at Chennai facility ends with zero observations: Natco Pharma
The inspection was conducted during the period July 8-12, 2019
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Natco Pharma
Panel discussion: From formulation development to commercialisation of complex generics: Challenges…
FDD Conclave, a one-of-its-kind platform for formulation development and drug delivery professionals, is a thought leadership…
Natco gets US FDA nod to market renal disease drug
The product, as the first generic, will be launched shortly in the US market
Natco Pharma CEO supports children’s eye care at LV Prasad Eye Institute
Donates 1.5 lakh shares valued at Rs 15 crores
Natco Pharma to sell US-based pharmacy stores
Financial details were not disclosed as well as reasons for sale of the assets
NATCO receives DCG(I) approval for hepatitis C drug
The company plans to launch this combination drug immediately, under its brand name Hepcinat LP
Natco Pharma has received…
Natco settles patent suit with Gilead, others
Under the terms of the settlement, Natco's partner Alvogen will be able to market the oseltamivir phosphate capsules
Natco Pharma…
Natco Pharma suspends work at Chennai plant due to flood
Company's API plant has temporarily suspended operations due to rains
Drug firm Natco Pharma said its active pharmaceuticals…
NATCO launches hepatitis C drug in Nepal
The company has signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015
Natco Pharma has launched the…
Natco Pharma plans five new products for US market
The Rs 850-crore company expects to see organic growth of 15-20 per cent
Natco Pharma is preparing to launch about four to five…